Bayer and Hologic, Inc., today announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions.
CEM is an innovative highly sensitive and low-cost breast imaging modality which combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.